A study led by the Gwangju Institute of Science and Technology (GIST) developed the new defect passivation strategy. The ...

Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

Gilead Sciences, Inc. has announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six ...

Researchers have developed a novel passivation process for formamidinium lead iodide perovskite films, which reportedly ...

Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to ...

Lenacapavir was approved for use in HIV-positive adults with multi-drug resistance by the European Union in August 2022 and ...

Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 11:30 Hrs [IST] US-based ...

Hetero has partnered with Gilead Sciences to manufacture and distribute the HIV drug lenacapavir in 120 low- and ...

Dr. Reddy's, Hetero, and Mylan partner with Gilead Sciences to manufacture generic lenacapavir for HIV prevention globally.